NICE green light for GSK’s Nucala
Final guidance on the drug’s use to treat patients with severe eosinophilic asthma on the NHS has now been published
Read More
Tag: mepolizumab
New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
FDA OKs new administration options for GSK’s Nucala
The two new methods, autoinjector and a pre-filled safety syringe, are for patients or caregivers to administer once every four weeks.
Read More
GSK files Nucala for wider paediatric use
GlaxoSmithKline is seeking to expand the use of its biologic Nucala in the US to include children aged six to 11 years with severe eosinophilic asthma.
Read More
Long-term data backs safety and efficacy of GSK’s Nucala
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control in patients taking its biologic Nucala.
Read More
US regulators reject GSK’s Nucala for COPD
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
Read More
FDA staff question efficacy of GSK’s Nucala for COPD
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).
Read More
Data show ‘enduring’ benefits of GSK’s Nucala
GlaxoSmithKline has released long-term data showing that its biologic Nucala significantly decreased exacerbations in patients with severe, eosinophilic asthma as well as improvement in disease control.
Read More
GSK’s Nucala improves control of severe asthma
GlaxoSmithKline has presented data showing that its biologic Nucala improved asthma control in patients with severe disease not adequately managed with Novartis’ Xolair.
Read More
FDA OK’s GSK’s asthma biologic for rare autoimmune disease
GlaxoSmithKline’s biologic Nucala has become the first therapy specifically approved in the US to treat a rare disease called eosinophilic granulomatosis with polyangiitis (EPGA).
Read More
GSK files Nucala for COPD
GlaxoSmithKline is seeking permission to market its asthma biologic mepolizumab for the treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in the US.
Read More
GSK tests mepolizumab for nasal polyps
GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
